Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 3
2005 2
2006 1
2007 3
2008 2
2009 2
2010 2
2011 2
2012 1
2013 1
2014 3
2015 3
2016 2
2017 2
2018 3
2019 5
2020 5
2022 3
2023 4
2024 6
2025 2
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Results by year

Filters applied: . Clear all
Page 1
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational study.
Pasello G, Proto C, Genova C, Pavan A, Roca E, Minuti G, D'Aniello C, Giusti R, Mariotti S, Romano FJ, Polo V, Belluomini L, Baldini E, Mazzoni F, Bettini AC, Gristina V, Russo A, Grossi F, Ogliari FR, Gelsomino F, Chiari R, Bria E, Fioroni I, Cortinovis D, Pizzutilo EG, Zanetti A, Pasqualetti G, Roncari B, Simoni L, Catino A; ELBA Study Group. Pasello G, et al. Among authors: baldini e. Front Oncol. 2026 Feb 16;16:1724019. doi: 10.3389/fonc.2026.1724019. eCollection 2026. Front Oncol. 2026. PMID: 41777656 Free PMC article.
Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial.
Mattioli C, Olmetto E, Banini M, Garlatti P, Caini S, Riccio MD, Finocchiaro G, Borghetti P, Pilotto S, Metro G, Grossi F, Farina G, Meriggi F, Chella A, Roca E, Zannori C, Delmonte A, Russo A, Macerelli M, Genova C, Cortinovis D, D'Arcangelo M, Del Conte A, Lugini A, Petrelli F, Vasile E, Iannopollo M, Taveggia PA, Quaquarini E, Baldini E, Ponzanelli A, Manzoni M, Cergnul M, Camerini A, Tartarone A, Inno A, Favaretto A, Veccia A, La Torre L, Perna M, Livi L, Bruni A, Scotti V. Mattioli C, et al. Among authors: baldini e. Cancer Treat Res Commun. 2026 Feb 7;47:101132. doi: 10.1016/j.ctarc.2026.101132. Online ahead of print. Cancer Treat Res Commun. 2026. PMID: 41707549 Free article.
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.
Sini C, Russo A, Cortinovis D, Muscarella LA, Tiseo M, Bria E, Grisanti S, Piovano P, Veccia A, Antonuzzo L, Citarella F, Pilotto S, Reale ML, Pignataro D, Roca E, Calvetti L, Pizzutilo P, Minuti G, Pelizzari G, Alì G, Bettini A, Pavan A, Signorelli D, Ricciardi S, Meoni G, Sergi C, Genova C, Scotti V, Vavalà T, Gori S, Pasello G, Pedrazzoli P, Chiari R, D'Aveni A, Buosi R, Toschi L, Parra HS, Buffoni L, Stanzione B, Ortega C, Zannori C, Giannarelli D, Malapelle U, Novello S, Passiglia F, Baldini E. Sini C, et al. Among authors: baldini e. Eur J Cancer. 2026 Feb 5;234:116191. doi: 10.1016/j.ejca.2025.116191. Epub 2025 Dec 24. Eur J Cancer. 2026. PMID: 41475048 Free article.
An open-label, randomized phase III study of early switch maintenance vs delayed second-line nivolumab in advanced stage squamous non-small cell lung cancer (NSCLC) patients after standard first-line platinum-based chemotherapy-EDEN trial GOIRC 04-2016.
Gelsomino F, Boni L, Tiseo M, Ricciardi S, Rocco D, Cortinovis DL, Proietto M, Cogoni A, Pasello G, Camerini A, Sperandi F, Colantonio I, Metro G, Mazzoni F, Baldini E, Veccia A, Bennicelli E, Cecilia Bettini A, Tognetto M, Ardizzoni A. Gelsomino F, et al. Among authors: baldini e. Lung Cancer. 2025 Jan;199:108059. doi: 10.1016/j.lungcan.2024.108059. Epub 2024 Dec 15. Lung Cancer. 2025. PMID: 39700681 Free article. Clinical Trial.
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Leonetti A, Perrone F, Puntoni M, Maglietta G, Bordi P, Bria E, Vita E, Gelsomino F, De Giglio A, Gelibter A, Siringo M, Mazzoni F, Caliman E, Genova C, Bertolini F, Guaitoli G, Passiglia F, Delcuratolo MD, Montrone M, Cerea G, Pasello G, Roca E, Belluomini L, Cecere FL, Guida A, Manzo A, Adamo V, Rastelli F, Bulotta A, Citarella F, Toschi L, Zoratto F, Cortinovis DL, Berardi R, Follador A, Carta A, Camerini A, Salerno F, Silva RR, Baldini E, Cortellini A, Brighenti M, Santoni M, Malorgio F, Caminiti C, Tiseo M. Leonetti A, et al. Among authors: baldini e. Eur J Cancer. 2024 May;202:114006. doi: 10.1016/j.ejca.2024.114006. Epub 2024 Mar 11. Eur J Cancer. 2024. PMID: 38489861
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression.
Del Re M, Luculli GI, Petrini I, Sbrana A, Scotti V, Perez DM, Livi L, Crucitta S, Iannopollo M, Mazzoni F, Ruglioni M, Tibaldi C, Olmetto E, Stasi I, Baldini E, Allegrini G, Antonuzzo L, Morelli F, Pierini A, Panzeri N, Fogli S, Chella A, Rolfo C, Danesi R. Del Re M, et al. Among authors: baldini e. Transl Oncol. 2024 Mar;41:101869. doi: 10.1016/j.tranon.2023.101869. Epub 2024 Jan 29. Transl Oncol. 2024. PMID: 38290249 Free PMC article.
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study.
Bersanelli M, Verzoni E, Cortellini A, Giusti R, Calvetti L, Ermacora P, Di Napoli M, Catino A, Guadalupi V, Guaitoli G, Scotti V, Mazzoni F, Veccia A, Guglielmini PF, Perrone F, Maruzzo M, Rossi E, Casadei C, Montesarchio V, Grossi F, Rizzo M, Travagliato Liboria MG, Mencoboni M, Zustovich F, Fratino L, Accettura C, Cinieri S, Camerini A, Sorarù M, Zucali PA, Ricciardi S, Russo A, Negrini G, Banzi MC, Lacidogna G, Fornarini G, Laera L, Mucciarini C, Santoni M, Mosillo C, Bonetti A, Longo L, Sartori D, Baldini E, Guida M, Iannopollo M, Bordonaro R, Morelli MF, Tagliaferri P, Spada M, Ceribelli A, Silva RR, Nolè F, Beretta G, Giovanis P, Santini D, Luzi Fedeli S, Nanni O, Maiello E, Labianca R, Pinto C, Clemente A, Tognetto M, De Giorgi U, Pignata S, Di Maio M, Buti S, Giannarelli D; FICOG group (Federation of Italian Cooperative Oncology Groups). Bersanelli M, et al. Among authors: baldini e. EClinicalMedicine. 2023 Jun 29;61:102044. doi: 10.1016/j.eclinm.2023.102044. eCollection 2023 Jul. EClinicalMedicine. 2023. PMID: 37434748 Free PMC article.
54 results